
Cancer Antibodies for Cancer Research



bioxcell.com

Antibodies for Cancer Research



Antigen	Reactivity	Application	Clone	InVivoMab Catalog	InVivoPlus Catalog
4-1BB (CD137)	mouse	in vivo activation of 4-1BB	LOB12.3	BE0169	BP0169
4-1BB (CD137)	mouse	in vivo and in vitro 4-1BB stimulation	3H3	BE0239	BP0239
4-1BB (CD137)	mouse	in vitro 4-1BB blockade, FC	17B5	BE0296	
4-1BBL (CD137L)	mouse	in vivo 4-1BBL blockade	TKS-1	BE0110	
B7-1 (CD80)	mouse	in vivo B7-1 blockade, Affinity chromatography	1G10	BE0134	
BTLA (CD272)	mouse	in vivo BTLA stimulation, in vivo BTLA blockade	6A6	BE0132	
BTLA (CD272)	mouse	in vivo and in vitro stimulation of BTLA, FC	PK18.6	BE0153	
BTLA (CD272)	mouse	in vivo BTLA blockade, in vitro T cell stimulation/activation, FC	PJ196	BE0196	
CD19	mouse	in vivo B cell depletion, in vivo CD19 neutralization, in vitro B cell negative selection, FC	1D3	BE0150	
CD19	human	FC, Functional assays, IF, Chimeric antigen receptor construction	4G7	BE0281	
CD20	mouse	in vivo B cell depletion, WB	MB20-11	BE0356	
CD20	human/monkey	in vivo B cell depletion in hCD20 Tg mice, IHC-F, IP, FC	2H7	BE0276	
CD20	mouse	FC, WB	AISB12	BE0302	
CD24	mouse	in vivo administration, IHC-F, IHC-P, IF, FC	M1/69	BE0360	
CD27		in vivo CD27 stimulation, in vitro CD27 stimulation, IP, FC	RM27-3E5	BE0348	
CD28	mouse	in vitro T cell stimulation/activation, in vivo CD28 blockade	37.51	BE0015-1	
CD28	mouse		PV-1	BE0015-5	
	mouse	in vitro T cell stimulation/activation	9.3		
CD28 CD28	human	in vitro T cell stimulation/activation	9.3 CD28.2	BE0248 BE0291	
	human/monkey	in vitro T cell stimulation/activation, FC, IHC-F, IP			
CD28	mouse	in vivo and in vitro T cell stimulation/activation	D665	BE0328	
CD38	mouse	in vivo and in vitro CD38 stimulation, in vitro B cell activation, IF	NIMR5	BE0317	
CD40	mouse	in vivo CD40 activation, in vitro B cell stimulation/activation	FGK4.5/FGK45	BE0016-2	BP0016-2
CD40L (CD154)	mouse	in vivo and in vitro blocking of CD40/CD40L signaling	MR-1	BE0017-1	BP0017-1
CD40L (CD154)	human/monkey	in vitro and in vivo blocking of CD40/CD40L signaling, IP, FC	5C8	BE0292	
CD44	mouse/human	in vivo CD44 neutralization	IM7	BE0039	
CD44	human	in vivo CD44 blockade in xenografts, in vitro CD44 blockade, WB, IF	Hermes-1	BE0262	
CD47	human	in vitro CD47 neutralization, in vivo CD47 neutralization in human tumor xenograft models or humanized mice, FC	B6H12	BE0019-1	
CD47	human/mouse/rat	in vivo CD47 blockade, in vitro CD47 blockade, IF	MIAP410	BE0283	BP0283
CD47 (IAP)	mouse	in vivo CD47 blockade, in vitro CD47 blockade, IF	MIAP301	BE0270	
CD69	mouse	in vivo down-regulation of CD69 expression, Functional assays	CD69.2.2	BE0330	
CD70	mouse	in vivo and in vitro CD70 blockade, FC	FR70	BE0022	
CD71 (TfR)	human	WB, IP, FC	5E9C11	BE0343	
CD71 (TfR1)	mouse	in vivo depletion of CD71+ cells	R17 217.1.3	BE0175	
CD71 (TfR1)	mouse	in vivo depletion of CD71+ cells, IF, IHC-F, WB	8D3	BE0329	
CD71 (TfR1)	rat/mouse	Targeted drug delivery to the brain, IHC-F, FC	OX-26	BE0331	
CD73	mouse	in vivo CD73 blockade	TY/23	BE0209	
CD80 (B7-1)	mouse	in vivo CD80 blockade, FC	16-10A1	BE0024	
CD86 (B7-2)	mouse	in vivo CD86 blockade, FC	GL-1	BE0025	
CD96	mouse	in vivo and in vitro CD96 blocking, FC	3.3	BE0337	
CD103	mouse	in vivo CD103 neutralization, IF, FC	M290	BE0026	
CD172a (SIRPα)	mouse	in vivo and in vitro SIRPα blocking, WB, IP, FC	P84	BE0322	
CD209b (SIGN-R1)	mouse	in vivo SIGN-R1 blockade, IHC-F, WB, FC	22D1	BE0220	
CD276 (B7-H3)	mouse	in vivo B7-H3 blockade, FC	MJ18	BE0124	
CD314 (NKG2D)	mouse	in vivo and in vitro NKG2D blockade, FC	CX5	BE0334	
CD326 (EpCAM)	mouse	IHC-F, IF, FC, WB	G8.8	BE0346	
c-Kit (CD117)	mouse	FC, IF, IHC	2B8	BE0280	
c-Kit (CD117)	mouse	in vivo mast cell depletion, in vivo c-Kit+ cell depletion, in vitro c-Kit neutralization, IP, FC	ACK2	BE0293	
c-myc	human	WB, ELISA, FC	9E10	BE0238	
CLEC9A (CD370)	mouse	in vivo Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC	7H11	BE0305	
CSF1R (CD115)	mouse	in vivo macrophage depletion, in vitro CSF-R1 neutralization, in vivo monocyte depletion, FC	AFS98	BE0213	BP0213

α-mouse PD-1 (BP0146)	α-mouse PD-L1 (BP0101)	InVivoMab vs. InVivoPlus		
148	148	InVivoMab purity level > 95%	InVivoPlus > 95%	
98 — 64 — 64 — 64 — 64 — 64 — 64 — 64 — 6	98	protein aggregates validated at ≤ 5%	V	
50 —	50 — PD-L1 (45 kDa)	azide and carrier protein free		
36 — PD-1 (45 kDa)	36 —	endotoxin concentration <2EU/mg	< 1EU/mg	
1960		validated by immunoblot, FC, or ELISA		
16 —	16 —	screened for murine pathogens	\checkmark	
6 Purified PD-1	6 Purified PD-L1	available in bulk quantities	\checkmark	

Antigen	Reactivity	Application	Clone	InVivoMab Catalog	InVivoPlus Catalog
CSF1R (CD115)	human	in vitro CSF1R neutralization, IHC-P, Functional assays, FC	2-4A5-4	BE0347	
CTLA-4 (CD152)	mouse	in vivo and in vitro CTLA-4 neutralization, FC	UC10-4F10-11	BE0032	BP0032
CTLA-4 (CD152)	mouse	in vivo and in vitro CTLA-4 neutralization	9H10	BE0131	BP0131
CTLA-4 (CD152)	mouse	in vivo CTLA-4 neutralization	9D9	BE0164	BP0164
CTLA-4 (CD152)	human	in vitro CTLA-4 neutralization, FC	BN13	BE0190	
DR5 (CD262)	mouse	in vivo and in vitro induction TRAIL-mediated apoptosis	MD5-1	BE0161	
EGFR	human	in vitro EGFR blockade, in vivo EGFR blockade in xenografts, WB, Functional assays	225	BE0278	
EGFR	human	in vitro EGFR blockade, in vivo EGFR blockade in xenografts, WB, Functional assays, IP, IHC-P, IF, FC	528	BE0279	
EphA2	human	IHC-P, IP, Functional assay	B2D6	BE0341	
E-Cadherin (CD324)	mouse	in vivo E-Cadherin neutralization, in vitro E-Cadherin neutralization, IF, IP, WB	DECMA-1	BE0352	
E-selectin (CD62E)	mouse	in vivo E-selectin blockade, in vitro E-selectin blockade, IHC-F	9A9	BE0294	
FasL (CD178)	mouse	in vivo and in vitro FasL blockade, Functional assay, IHC-P, FC	MFL3	BE0319	
FGL-1	mouse	in vivo and in vitro FGL-1 blockade, FC, IHC-P	177R4	BE0332	
Galectin-9	mouse	in vivo and in vitro Galectin-9 blockade	RG9-1	BE0218	
GITR	mouse	in vivo GITR stimulation	DTA-1	BE0063	BP0063
GM-CSF	mouse	in vivo and in vitro GM-CSF neutralization, FC	MP1-22E9	BE0259	
HER2 (neu)	human/rat	in vivo and in vitro HER2/neu inhibition, IP, IF, FC	7.16.4	BE0277	
ICOS	mouse	in vivo blocking of ICOS/ICOSL signaling, FC	7E.17G9	BE0059	
ICOSL (CD275)	mouse	in vivo ICOSL neutralization	НК5.3	BE0028	
IL-7Rα (CD127)	mouse	in vivo blocking of IL-7Rα signaling, FC	A7R34	BE0065	
IL-17F	mouse	in vivo IL-17F neutralization	MM17F8F5.1A9	BE0303	
IL-27 p28	mouse	in vivo and in vitro IL-27 p28 neutralization, FC	MM171013.147	BE0326	
· · ·		in vivo Jagged 2 neutralization	HMJ2-1	BE0125	
Jagged2 LAG-3	mouse	in vivo adgeo 2 neutralization	C9B7W	BE0123	BP0174
	mouse			BE0034	BF0174
LPAM-1 (Integrin α4β7)	mouse	in vivo Integrin α487 neutralization, FC	DATK32		
LRP1 (CD91)	mouse/human/rat		11H4	BE0333	BD0075 1
Ly6G	mouse	in vivo neutrophil depletion, in vivo MDSC depletion, IF, IHC-P, IHC-F, FC	1A8	BE0075-1	BP0075-1
Ly6G/Ly6C (Gr-1)	mouse	in vivo neutrophil depletion, IHC-P, IHC-F, IF, FC	NIMP-R14	BE0320	BB007 (
Ly6G/Ly6C (Gr-1)	mouse	in vivo depletion of Gr-1+ myeloid cells, FC, IHC-P, IHC-F	RB6-8C5	BE0075	BP0076
MAGEC2 (CT10)	human	IHC-P, IF, WB	LX-CT10.5	BE0335	
MDR-1 (CD243)	human/monkey	in vivo MDR-1 blocking/depletion in xenogeneic murine tumor models, in vitro MDR-1 blocking, IHC-P	UIC2	BE0340	
MUC1 (CD227)	human	in vivo administration in mouse xenograft models, IHC-P, IF, in vitro cell cytotoxicity assay,WB	C595 (NCRC48)	BE0336	
NKG2A/C/E	mouse	in vivo and in vitro NKG2A blockade, IHC-F, FC	20D5	BE0321	
NKG2D	mouse	in vivo NKG2D blockade	HMG2D	BE0111	
PD-1 (CD279)	mouse	in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization	J43	BE0033-2	BP0033-3
PD-1 (CD279)	mouse	in vivo blocking of PD-1/PD-L signaling	RMP1-14	BE0146	BP0146
PD-1 (CD279)	human	in vitro PD-1 neutralization, in vivo PD-1 blockade in humanized mice	J116	BE0188	
PD-1 (CD279)	human	in vivo PD-1 blockade in humanized mice, FC	J110	BE0193	
PD-1 (CD279)	mouse	in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, IHC-F, FC, WB	29F.1A12	BE0273	BP0273
PD-L1 (B7-H1)	mouse	in vivo PD-L1 blockade, IF, IHC-F, FC	10F.9G2	BE0101	BP0101
PD-L1 (B7-H1)	human	in vitro PD-L1 blockade, Functional assays, IHC-F, FC	29E.2A3	BE0285	
PD-L2 (B7-DC)	mouse	in vivo and in vitro PD-L2 blockade, IHC-F, FC	TY25	BE0112	
RANKL (CD254)	mouse	in vivo RANKL blockade	IK22/5	BE0191	
TIM-1 (CD365)	mouse	in vivo TIM-1 neutralization	RMT1-10	BE0113	
TIM-1 (CD365)	mouse	in vivo and in vitro TIM-1 blockade	3D10	BE0314	
TIM-3 (CD366)	mouse	in vivo TIM-3 neutralization, in vitro TIM-3 blocking, FC	RMT3-23	BE0115	BP0115
ΤΝFα	mouse/rat/rabbit	in vivo TNFα neutralization, FC	TN3-19.12	BE0244	
VEGFR-2	mouse	in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling	DC101	BE0060	BP0061
VISTA	mouse	in vivo and in vitro blocking of VISTA signaling, FC	13F3	BE0310	BP0310
VLDL-R	mouse/rat/bovine	WB	lgG-6A6	BE0345	



For over 20 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in over 15,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.

Bio X Cell bioxcell.com | 1.866.787.3444 customerservice@bioxcell.com



Conditions: For Research Use Only. Not for use in diagnostic or theraputic procedures. Not for resale. Bio X Cell, Bio X Cell Logo and all other trademarks are the property of Bio X Cell. © Bio X Cell 2021